 | |
| Clinical data | |
|---|---|
| Other names | 5-Azabicalutamide |
| Drug class | Nonsteroidal antiandrogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C17H13F4N3O4S |
| Molar mass | 431.36 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
5N-Bicalutamide, or5-azabicalutamide, is a highly potentnonsteroidal antiandrogen (NSAA) which was discovered in 2016.[1][2] It is astructural modification ofbicalutamide differing it from it only by the replacement of acarbon atom with anitrogen atom in one of itsphenyl rings.[1] Similarly to bicalutamide, the drug acts as aselectiveantagonist of theandrogen receptor (AR).[1] However, unlike bicalutamide, it is areversible covalent antagonist and stays bound to the receptor for a far longer amount of time.[1] As a result of this difference, 5N-bicalutamide has markedly improvedpotency relative to bicalutamide, with approximately 150-fold higheraffinity for the AR (Ki = 0.15 nM versus 22.3 nM) and about 20-fold greater functional inhibition (IC50Tooltip Half-maximal inhibitory concentration = 15 nM versus 310 nM) of the AR.[1] Future studies of 5N-bicalutamide in normal andmutatedprostate cancercells are planned or underway and it is anticipated thatN-bicalutamide may be able to overcome resistance.[1] to current antiandrogens that are used in the treatment of prostate cancer.[1]
Enzalutamide and relatedsecond-generation NSAAs likeRD-162 andapalutamide were derived from bicalutamide and as a result are similar to it inchemical structure.[1] They have up to about 10-fold higher affinity for the AR than does bicalutamide and hence are comparatively more potent andefficacious antiandrogens.[1] However, their structures are rigidified such that the analogous structural modification that was done with bicalutamide to create 5N-bicalutamide could not be used to increase affinity or potency with them.[1] Enzalutamide was described in 2013 as "the emperor of all antiandrogens" and other second-generation NSAAs have similar potency to it,[3] so 5N-bicalutamide would appear to be among the most potent AR antagonists to have been developed thus far.[1]
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
